ATS — ATS Corporation

ATS Corporation Q2 2026 Earnings Call Summary

1. Key Financial Results and Metrics:

• Order Bookings: $734 million, up 6% sequentially, but down 1.1% year-over-year due to fewer large enterprise orders.
• Revenue: $729 million, an 18.9% increase from Q2 last year, driven by 12.6% organic growth, 3.9% from foreign exchange, and 2.4% from acquisitions.
• Adjusted Earnings from Operations: $79.1 million, a 40% increase year-over-year.
• Gross Margin: 29.9%, up 36 basis points from the previous year.
• Earnings Per Share (EPS): $0.45 on an adjusted basis.
• Order Backlog: Approximately $2.1 billion, providing good revenue visibility.
• Net Debt to Adjusted EBITDA Ratio: 3.4x, with a target to reduce to 2-3x by fiscal year-end.

2. Strategic Updates and Business Highlights:

• Leadership Transition: Ryan McLeod is serving as Interim CEO while a search for a permanent CEO is ongoing.
• Market Performance: Strong performance noted in Life Sciences, Food and Beverage, and Energy sectors, particularly in nuclear refurbishment projects.
• Innovation Focus: Continued investment in the Illuminate Manufacturing intelligence platform and the opening of the Comecer Competence Center in Indianapolis to enhance service capabilities.
• M&A Activity: The company is actively reviewing acquisition opportunities while focusing on reducing leverage.

3. Forward Guidance and Outlook:

• Q3 Revenue Expectations: Anticipated to be between $700 million and $740 million.
• Full-Year Revenue Growth: High single-digit growth is expected, with continued margin improvement anticipated for fiscal 2026.
• Restructuring Costs: Approximately $15 million expected in the second half of the fiscal year to realign the cost structure.

4. Bad News, Challenges, or Points of Concern:

• Bookings Momentum: There is concern regarding the slowdown in bookings momentum over the past six months compared to the previous year, attributed to timing and execution of larger orders.
• Government Funding Impact: Some government-funded customers are taking a more cautious approach to capital investment, which could affect future order volumes.
• Working Capital Efficiency: The company aims to improve noncash working capital as a percentage of revenues to 15%, facing challenges from timing of milestone billings and collections.

5. Notable Q&A Insights:

• Customer Feedback on GLP-1s: There is ongoing development for oral alternatives to GLP-1 therapies, but auto-injectors remain the preferred delivery method due to challenges with oral formulations.
• Nuclear Segment Growth: The nuclear backlog is expected to contribute significantly to revenue growth, with a mix of refurbishment and new build projects.
• SG&A Management: The company aims to achieve better leverage on SG&A expenses, ensuring that growth in these costs does not outpace revenue growth.

Overall, ATS Corporation's Q2 2026 results reflect strong revenue growth and a healthy order backlog, although there are concerns regarding slowing bookings and the impact of government funding on certain segments. The company is focused on strategic growth initiatives, innovation, and improving operational efficiencies moving forward.